IGTP-led study identifies an epigenetic signature with prognostic value in metastatic thyroid cancer
Researchers from the Endocrine Tumours group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with five university hospitals, have conducted the first comprehensive study of ...
Real-world treatment outcomes and clinicopathologic determinants of response for patients with advanced thyroid cancer treated with first-line lenvatinib. This is an ASCO Meeting Abstract from the ...
The efficacy and safety of anti–PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study. This is an ASCO Meeting Abstract from ...
Outcome and therapy prediction using MAP score. Summary diagram showing the potential role of MAP score for risk stratifying thyroid tumors. Credit: Cell Genomics (2023). DOI: ...
Recurrent IRTC invading the upper aerodigestive tract remains a formidable clinical challenge. Management typically involves tracheal resection or laryngectomy, often with sacrifice of the recurrent ...
CHICAGO — The targeted agent sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals) could become the first new drug for metastatic thyroid cancer in 40 years and opens up a new field in medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results